Avidity Biosciences, Inc. — Director's Dealing 2020

Jun 16, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Avidity Biosciences, Inc. (RNA)
CIK: 0001599901
Period of Report: 2020-06-16

Reporting Person: WILSON TROY EDWARD (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-06-16	Common Stock	C	189042	—	Acquired	805301	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-06-16	Series A Preferred Stock	$	C	254907	Disposed		Common Stock (120837)	Indirect
2020-06-16	Series B Preferred Stock	$	C	35374	Disposed		Common Stock (16769)	Indirect
2020-06-16	Series C Preferred Stock	$	C	108504	Disposed		Common Stock (51436)	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	189618	Direct
Common Stock	35553	Indirect
Common Stock	35553	Indirect
Common Stock	11851	Indirect
Common Stock	11851	Indirect

Footnotes

F1: The shares of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of one-for-2.1095 shares, immediately prior to the consummation of the Issuer's initial public offering.

F2: Includes 59,256 shares subject to repurchase by the Issuer, which shares will vest in 15 equal monthly installments beginning on June 29, 2020.